Fiche société
BeOne Medicines
Traitements, essais et publications liés.
Traitements14programmes
Essais8liés
Publications22liées
SourceDBlocale
Traitements
14| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| BendamustineResearchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy) | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, Czechia, Germany, Italy, … | À vérifier |
| IdelalisibThe purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i). | Cancer | Phase 3 | Immunomodulation | United States, Argentina, Australia, Brazil, Canada, Czechia, Germany, Italy, … | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | Cancer, Lupus, Myasthénie, SEP | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, Czechia, Germany, Italy, … | À vérifier |
| SonrotoclaxThe purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL). | Cancer | Phase 3 | À vérifier | United States, Australia, Brazil, Canada, China, Czechia, France, Germany, … | À vérifier |
| TacabrutidegStudy consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts) | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, Czechia, Germany, Italy, … | À vérifier |
| VenetoclaxThis study evaluates the effectiveness and safety of a new conditioning regimen called VABu before stem cell transplantation in patients with acute myeloid leukemia (AML) who are in their first complete remission (CR1), classified as non-high-risk per ELN 2022 guidelines, but have poor physical condition (ECOG performance status ≥ 2) or high comorbidity burden (HCT-CI ≥ 2). VABu combines venetoclax, azacitidine (or decitabine as an alternative), and busulfan. This is a single-arm, prospective study with 42 participants. All participants will receive the VABu regimen followed by stem cell transplantation. The primary outcome measure is 2-year overall survival (OS). Secondary outcomes include 2-year relapse-free survival (RFS), transplant-related mortality (TRM), engraftment failure rate, bloodstream infection (BSI), and 2-year all-cause mortality and non-relapse mortality (NRM). The study is conducted at the First Affiliated Hospital of Soochow University. | Cancer | Phase 3 | Thérapie cellulaire | United States, Argentina, Australia, Brazil, Canada, Czechia, Germany, Italy, … | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | Myasthénie | Phase 3 | À vérifier | Italy | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | Lupus | NA | À vérifier | À vérifier | |
| VenetoclaxThis study evaluates the effectiveness and safety of a new conditioning regimen called VABu before stem cell transplantation in patients with acute myeloid leukemia (AML) who are in their first complete remission (CR1), classified as non-high-risk per ELN 2022 guidelines, but have poor physical condition (ECOG performance status ≥ 2) or high comorbidity burden (HCT-CI ≥ 2). VABu combines venetoclax, azacitidine (or decitabine as an alternative), and busulfan. This is a single-arm, prospective study with 42 participants. All participants will receive the VABu regimen followed by stem cell transplantation. The primary outcome measure is 2-year overall survival (OS). Secondary outcomes include 2-year relapse-free survival (RFS), transplant-related mortality (TRM), engraftment failure rate, bloodstream infection (BSI), and 2-year all-cause mortality and non-relapse mortality (NRM). The study is conducted at the First Affiliated Hospital of Soochow University. | Cancer | Non applicable | Thérapie cellulaire | China | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 3 | À vérifier | Netherlands | À vérifier |
| TacabrutidegStudy consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts) | Cancer | Phase 1/2 | À vérifier | United States, Australia, Brazil, Canada, China, France, Georgia, Germany, Italy, Japan, Moldova, South Korea, Spain, Sweden, Turkey (Türkiye), United Kingdom | À vérifier |
| SonrotoclaxThe purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL). | Cancer | Phase 3 | À vérifier | United States, Australia, Brazil, Canada, China, Czechia, France, Germany, Italy, Netherlands, New Zealand, Poland, Romania, South Korea, Spain, Sweden, United Kingdom | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 3 | À vérifier | Denmark | À vérifier |
| TacabrutidegStudy consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts) | Cancer | Phase 3 | Immunomodulation | United States, Argentina, Australia, Brazil, Canada, Czechia, Germany, Italy, Japan, Netherlands, Poland, South Korea, Turkey (Türkiye), United Kingdom | À vérifier |
Essais cliniques
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Tacabrutideg | Cancer | Phase 3 | NCT06846671 | CaDAnCe-302 — A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | RECRUITING |
| Rituximab | SEP | Phase 3 | NCT04688788 | DanNORMS — Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Sonrotoclax | Cancer | Phase 3 | NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | RECRUITING |
| Tacabrutideg | Cancer | Phase 1/2 | NCT05006716 | CaDAnCe-101 — A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | RECRUITING |
| Rituximab | SEP | Phase 3 | NCT05834855 | Noisy Rebels — Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS | RECRUITING |
| Venetoclax | Cancer | Non applicable | NCT07762508 | A Prospective Single-Arm Study of VABu Conditioning Regimen in Allo-HSCT for Low-Performance or High-Comorbidity AML Patients in CR1 | NOT_YET_RECRUITING |
| Rituximab | Lupus | NA | NCT00908986 | Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis | WITHDRAWN |
| Rituximab | Myasthénie | Phase 3 | NCT05868837 | Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) | RECRUITING |
Publications
22| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Bendamustine | A dual green chromatographic platform for bioanalytical quantification and pharmacokinetic characterization of the BBD antineoplastic regimen. | Analytica chimica acta | ||
| Bendamustine | Comparative pathogenesis and management of orbital/conjunctival and gastric MALT lymphoma: Microbial drivers, molecular mechanisms, and therapeutic implications. | Survey of ophthalmology | ||
| Bendamustine | Follicular Lymphoma Arising in an Ileal Neobladder Presenting as a Large Pelvic Mass. | IJU case reports | ||
| Venetoclax | Identification of long non-coding RNAs involved in leukemogenesis and venetoclax response in acute myeloid leukemia through functional CRISPR-dCas9 interference screens. | Non-coding RNA research | ||
| Venetoclax | Development of highly selective, low-toxicity and orally available Mcl-1 inhibitors based on 3,5-dimethyl-4-sulfonimide-1H-pyrrole scaffold via P2/P3 dual pocket binding optimization. | European journal of medicinal chemistry | ||
| Venetoclax | Age-dependent clinical, molecular, and prognostic differences in patients with AML: a retrospective study. | Hematology (Amsterdam, Netherlands) | ||
| Rituximab | Proteinuria selectivity index as a predictor of remission and rituximab efficacy in primary membranous nephropathy: a single-center retrospective analysis. | Renal failure | ||
| Rituximab | Rituximab remodels the circulating immune landscape in pemphigus vulgaris revealed by high-dimensional immune profiling. | Journal of translational autoimmunity | ||
| Rituximab | Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma. | Oncoimmunology | ||
| Rituximab | [An unusual cause for unilateral eye pain with double vision]. | Praxis | ||
| Rituximab | Immunoglobulin G4-Related Sclerosing Cholangitis: A Review. | Clinics in liver disease | ||
| Rituximab | Use of avacopan in granulomatosis with polyangiitis with predominant gastrointestinal and kidney involvement. | BMJ case reports | ||
| Rituximab | Case Report: Severe ANCA-positive eosinophilic granulomatosis with polyangiitis presenting with Loeffler endocarditis and cryofibrinogenemia-associated digital gangrene successfully treated with rituximab. | Frontiers in immunology | ||
| Rituximab | Post-transplant lymphoproliferative disorder after solid organ transplantation: a comprehensive review. | Frontiers in transplantation | ||
| Rituximab | Severe Immune-Mediated Thrombotic Thrombocytopenic Purpura With High-Titer ADAMTS13 Inhibitors: A Case Report. | Cureus | ||
| Rituximab | Efficacy of Rituximab in Successful Management of Refractory Juvenile Systemic Lupus Erythematosus Complicated with Macrophage Activation Syndrome: A Case Report with Literature Overview. | Indian journal of dermatology | ||
| Rituximab | Fulminant paraneoplastic Ma2 (PNMA2) and zinc finger protein of the cerebellum 4 (ZIC4) antibody-positive encephalitis in triple-negative breast cancer treated with pembrolizumab. | BMJ case reports | ||
| Rituximab | Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab. | Kidney international reports | ||
| Rituximab | [Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits (PGNMID) Associated with Marginal Zone B-cell Lymphoma: A Case of MGRS in a Patient with Nephrotic Syndrome and Rapidly Progressive Renal Failure]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia | ||
| Rituximab | Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies. | Expert opinion on biological therapy | ||
| Rituximab | Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias. | Annals of hematology | ||
| Rituximab | Evaluation of the comparative efficacy and safety of obinutuzumab and other follow-up strategies after rituximab failure in refractory nephrotic syndrome. | Pediatric nephrology (Berlin, Germany) |